// added the section below on July 01 2024 // till here on July 01 2024

Vaccines Market

Vaccines Market Distribution by Type of Vaccine (Pneumococcal Conjugate Vaccine, Human Papilloma Virus Vaccine, Influenza Vaccine, Rotavirus Vaccine, Varicella Vaccine, DTP-HepB-Hib Vaccine, Meningococcal Group A, C, Y and W-135 Vaccine and Others), Type of Vaccine API (Live Attenuated Vaccine, Inactivated Vaccine, Conjugate Vaccine, Subunit Vaccine, Toxoid Vaccine and Others), Route of Administration (Intramuscular, Subcutaneous, Oral, Intranasal, Intradermal and Others), Target Patient Population (Pediatric and Adults) and Key Geographical Regions: Industry Trends and Global Forecasts, 2020-2030

  • Lowest Price Guaranteed From USD 4,899

  • Pages

  • View Count

Vaccines Market Overview

The vaccines market is estimated to be worth $94 billion in 2030, driven by the rise in the global population increasing the demand for preventive vaccines. Vaccines are versatile preventive formulations that have, so far, enabled the global eradication of smallpox (1980) and polio (2015), which are both debilitating viral diseases. According to the WHO, currently, global vaccination coverage is nearly 85%. This is believed to be responsible for preventing close to three million deaths, which would have otherwise been caused by infectious diseases, such as chickenpox, diphtheria, measles, pneumonia, tetanus, and tuberculosis. In fact, recent immunization records indicate that more than 115 million children are immunized against diphtheria, tetanus and pertussis annually. However, vaccine development, especially against newly identified pathogens, is a challenging and time consuming process. For instance, authorities claim that although there are many initiatives investigating vaccines against the recently identified SARS-CoV-2 coronavirus strain, a viable vaccine is still a year away. Other barriers to vaccine development include lack of pathogen specific information, inadequate immunity (conferred by certain types of vaccines), existence of multiple pathogenic strains, and reversion potential (a phenomenon where a weakened pathogen intended for use as a vaccine, reverts to its infectious phenotype). 

The context of Global Preventive Vaccines Market report, published by Roots Analysis List of Clinical-Stage Vaccine Candidates from the research report of Roots Analysis Current market landscape of Preventive Vaccines domain, prepared by Roots Analysis

Despite the success achieved, so far, through vaccination, it is estimated that over 1.5 million children, under the age of five, die of vaccine-preventable diseases, every year. This is largely attributed to storage (loss of efficacy upon prolonged storage) and logistics-related (cold chain requirement) complexities, which impact adequate distribution and transportation of such medications to remote areas. Given the rate at which the global population is growing, the demand for vaccines is anticipated to increase significantly. In this regard, significant strides have been made in improving existing vaccine formulations, mostly focused on enhancing stability. Recent technical advances, especially in the field of biotechnology, have heralded a new era in immunogen design for vaccine development. Moreover, many developers claim to be working on next generation preventive vaccine candidates, such as recombinant vaccines, viral vector-based vaccines and DNA vaccines, which have been demonstrated to elicit powerful immune responses, resulting in the development of immunologic memory. Further, a variety of adjuvants (substances with the innate potential to augment an immune response) have been discovered and are now available for the development of more versatile vaccine formulations. Several regional government bodies and private investors are actively financing stakeholders in vaccine industry. Given that in the recent past there has been a marked rise in new entrants in this field, we anticipate this market to witness substantial market growth during the forecast period.

Key Companies in Vaccines Market 

Examples of key vaccine companies engaged in preventive vaccines market (which have also been profiled in this market report; the complete list of vaccine companies is available in the full report) include Bio Farma, Emergent BioSolutions, GC Pharma, GlaxoSmithKline, Janssen, Merck, Novavax, Pfizer, Sanofi Pasteur and Valneva. This market report includes an easily searchable excel database of all the vaccine companies providing preventive vaccines, worldwide.

Recent Developments in Preventive Vaccines Market:

Several recent developments have taken place in the field of preventive vaccines market. We have outlined some of these recent initiatives below. These developments, even if they took place post the release of our market report, substantiate the overall market trends that have been outlined in our analysis.

  • In September 2023, Pfizer and BioNTech received the US FDA approval for 2023-2024 COVID-19 Vaccine. 
  • In August 2023, Merck announced the US Food and Drug Administration (FDA) has approved ERVEBO®, an Ebola Zaire Vaccine, used for the treatment of children 12 months of age and older. 
  • In August 2023, Pfizer announced US Food and Drug Administration (FDA) approval of maternal vaccine with an aim to prevent the development of lower respiratory tract disease caused by respiratory syncytial virus (RSV) in infants from birth to age 6 months.

Scope of the Report

The ‘Global Preventive Vaccines Market, 2020-2030’ market report features an extensive study of the current market landscape, market size, market share, market growth, market trends, market value, market forecast, market outlook, statistics and future opportunities of the vaccines market. The market research report also features a detailed analysis of the key drivers and trends related to this evolving segment of the pharmaceutical industry. Amongst other elements, the market research report includes:

Competitive analysis of Preventive Vaccine Developer, from Roots Analysis report This image provides information on funding and investments received by the companies engaged in Preventive Vaccines Market This image provides information about completed, ongoing and planned clinical studies of Preventive Vaccines
  • A detailed assessment of the current market landscape, including information on type of developer (industry, non-industry, industry / non-industry), phase of development (phase I, phase I/II, phase II, phase II/III, phase III and preregistration) of lead candidates, route of administration (intramuscular, intranasal, oral, intradermal, subcutaneous, intravenous and others), type of vaccine API (live, attenuated vaccine, recombinant vaccine, conjugate vaccine, inactivated vaccine, DNA vaccine, peptide vaccine, subunit vaccine, mRNA vaccine, toxoid vaccine and others), dosage form (ready to use liquid, lyophilized powder, nasal spray, capsule and tablet), dosage (single dose, 2 doses, 3 doses, 4 doses, 5 doses and 6 doses), target disease indication and target patient population (children, adults and seniors).
  • A competitiveness analysis of preventive vaccine developers, taking into consideration supplier strength (based on company size and its experience in this field) and pipeline strength (based on the number of clinical-stage vaccine candidates, highest phase of development, number of compatible routes of administration, number of indications evaluated, number of APIs evaluated and target patient population).
  • Elaborate profiles of the key preventive vaccine developers (shortlisted based on a proprietary criterion) across North America, Europe and Asia Pacific. Each profile includes a brief overview of the company, its year of establishment, location of headquarters, number of employees and financial information (if available). In addition to this, the profile includes information on the various clinical-stage vaccine candidates developed by the company. Further, we have provided the recent developments of the company and an informed future outlook.
  • A detailed analysis of more than 1,400 completed, ongoing and planned clinical studies of preventive vaccines, highlighting prevalent trends across various relevant parameters, such as trial registration year, phase of development, trial recruitment status, study design, trial focus area, type of preventive vaccine (based on pathogen), target disease indication(s),  type of sponsor / collaborator, leading industry sponsors / collaborators (in terms of number of trials conducted), enrolled patients population and regional distribution.
  • An overview of the ongoing vaccine development initiatives for complex conditions, such as COVID-19, ebola virus disease, HIV/AIDS, malaria and zika virus infection, including information on disease, its global burden, current treatment landscape and preventive vaccine research landscape. Further, we have provided the information on investments made and recent developments in vaccines market.
  • An analysis of the investments made in vaccines market, during the period between 2015 and 2020 (till March), including seed financing, venture capital financing, debt financing, grants, capital raised from IPOs and subsequent offerings, at various stages of development in vaccine companies that are engaged in developing preventive vaccines. 
  • A case study on contract manufacturing landscape for vaccines, featuring a comprehensive list of active CMOs and analyses based on a number of parameters, such as year of establishment, company size, scale of operation (preclinical, clinical and commercial), geographical location, number of vaccine manufacturing facilities, types of services offered (cell / virus banking, analytical development / testing, formulation, process development, fill / finish and regulatory filings), type of expression systems used for vaccine production (mammalian, microbial and others) and type of vaccine manufactured.

The key objective of vaccines market report is to provide a detailed market analysis in order to estimate the existing market size, market share, market growth, market trends, market value, market forecast, market outlook, statistics and future opportunity for vaccines market during the forecast period. Based on several parameters, such as target consumer segments, region specific adoption rates and expected prices of such products, we have provided an informed estimate on the likely evolution of the market over the forecast period 2020-2030. The market report also provides details on the likely distribution of the current and forecasted opportunity across [A] route of administration (intramuscular, subcutaneous, oral, intranasal, intradermal and others), [B] type of vaccine (pneumococcal conjugate vaccine, human papilloma virus vaccine, influenza vaccine, rotavirus vaccine, varicella vaccine, DTP-HepB-Hib vaccine, meningococcal group A, C, Y and W-135 vaccine and others), [C] type of vaccine API (live attenuated vaccine, inactivated vaccine, conjugate vaccine, subunit vaccine, toxoid vaccine and others), [D] target patient population (pediatric and adults) and [E] key geographical regions, covering North America (the US, Mexico and Canada), Europe (Spain, the UK, Italy, France, Germany and rest of Europe), Asia Pacific (India, China, Australia and rest of Asia Pacific), and rest of the world. In order to account for future uncertainties and to add robustness to our model, we have provided three forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth.

Frequently Asked Questions

Question 1: What are preventive vaccines?

Answer: Preventive vaccines are therapeutic interventions which when administered to the patient, prevent the occurrence of a viral disease condition.

Question 2: What is the anticipated market size for global vaccines market?

Answer: The global vaccines market size is estimated to be worth $94 billion in 2030.

Question 3: Who are the leading companies developing preventive vaccines?

Answer: Examples of key companies engaged in developing vaccines (which have also been profiled in this market report; the complete list of companies is available in the full report) include Bio Farma, Emergent BioSolutions, GC Pharma, GlaxoSmithKline, Janssen, Merck, Novavax, Pfizer, Sanofi Pasteur and Valneva.

Question 4: How many vaccine candidates are currently under clinical evaluation by the companies engaged in preventive vaccines market?

Answer: More than 200 vaccine candidates are currently under clinical evaluation by the companies engaged in preventive vaccines market.

Question 5: How many clinical trials evaluating preventive vaccines have been registered till date?

Answer: Till date, more than 1,400 clinical trials for evaluating preventive vaccines have been registered.

Question 6: How much money has been invested by stakeholders in the vaccines market?

Answer: Over USD 10 billion has been invested by stakeholders in the preventive vaccines market, highlighting the growing interest of players in this industry.


This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print Read more about Single-User License

This license grants the right of use of the purchased report by the employees of a business unit at a particular site/office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple Read more about One Location Site License

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm/enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the Read more about Enterprise License

Discounts available for multiple report purchases
Click here to send an email to Roots Analysis team. sales@rootsanalysis.com